AC
GMAB icon

AlphaCore Capital’s Genmab GMAB Stock Holding History

AlphaCore Capital’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,984
Closed -$554K – 1344
2025
Q4 		$554K Sell
17,984
-2,451
-12% -$76.4K 0.01% 587
2025
Q3 		$627K Buy
20,435
+18,313
+863% +$446K 0.02% 401
2025
Q2 		$43.8K Buy
+2,122
New +$43.6K ﹤0.01% 832

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $10.6B AUM 19.39% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AlphaCore Capital's GMAB Position: Q1 2026 in Review

AlphaCore Capital sold out of Genmab (GMAB) in Q1 2026, closing a stake of 17,984 shares — an estimated $554K sold.

AlphaCore Capital first reported a position in GMAB in Q2 2025 and held it in 3 quarters. The position peaked at $627K in Q3 2025. 274 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • AlphaCore Capital reported no remaining Genmab position as of Q1 2026 after selling out during the quarter.
  • AlphaCore Capital sold 17,984 Genmab shares in Q1 2026, an estimated $554K.
  • AlphaCore Capital first reported a position in Genmab in Q2 2025 and held it in 3 quarters.
  • AlphaCore Capital's Genmab position peaked at $627K in Q3 2025.
  • 274 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on AlphaCore Capital's 13F filing for Q1 2026, filed 15 May 2026.